HIMSHIMSHealthcare · Drug Manufacturers - Specialty & Generic

HIMS Stock Forecast: Hims & Hers Health, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$17
−2.85% on the day

The 15 Wall Street analysts covering Hims & Hers Health, Inc. hold a median 12-month price target of $26 — +52.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 17 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.1B
Ticker Nerd rank
12/ 100
Median analyst target
$26
Analysts covering
15
Revenue$753.2M+38.2% y/y
Operating income−$97.2M
Net income−$86.3M
Free cash flow−$68.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−18.1%
1M
−39.3%
YTD
−47.5%
1Y
−53.0%
From 52W high
−57.4%
From 52W low
+17.4%
$15
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HIMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Hims & Hers Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
12/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
58
Value
43
Quality
42
Growth
36
Revisions
30
Size
25
Momentum
19
Issuance
18
Volatility
9

Accruals (58): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (9): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HIMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HIMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26HIMSHigh $40Median $26Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
3 Buy12 Hold0 Sell
Low $23Median $26High $40

The green dot is the last close — the median target sits +52.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
10 Nov 2026Evercore ISI GroupMaintainsIn-Line$24 → $27
10 Nov 2026JefferiesMaintainsHold$31 → $24
10 Nov 2026Morgan StanleyMaintainsEqual-Weight$28 → $25
10 Nov 2026NeedhamMaintainsBuy$42 → $32
11 Sept 2026JP MorganAssumesNeutral$32
24 Aug 2026Truist SecuritiesMaintainsHold—
24 Aug 2026Truist SecuritiesMaintainsHold$27 → $32
21 Aug 2026BarclaysMaintainsOverweight—
21 Aug 2026BarclaysMaintainsOverweight$39 → $35
11 Aug 2026B of A SecuritiesMaintainsNeutral—
11 Aug 2026B of A SecuritiesMaintainsNeutral$30 → $32
11 Aug 2026CitigroupMaintainsNeutral—
11 Aug 2026CitigroupMaintainsNeutral$35 → $33
11 Aug 2026Deutsche BankMaintainsHold$25 → $26
11 Aug 2026Deutsche BankMaintainsHold—
11 Aug 2026Morgan StanleyMaintainsEqual-Weight—
11 Aug 2026Morgan StanleyMaintainsEqual-Weight$21 → $28
11 Aug 2026NeedhamMaintainsBuy—
11 Aug 2026NeedhamMaintainsBuy$35 → $42
11 Aug 2026TD CowenMaintainsHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

HIMS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HIMS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Hims & Hers Health, Inc. returned −53.0% against +12.2% for the S&P 500, dividends included.

HIMS vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26HIMSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HIMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Hims & Hers Health, Inc. (HIMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
57.1×

Cheaper than 12% of US stocks

Price / sales
1.4×

Cheaper than 58% of US stocks

Price / book
11.6×

Cheaper than 7% of US stocks

EV / EBITDA
−65.7×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
48.6%

Higher than 85% of US stocks

Earnings growth (YoY)
38.2%

Higher than 71% of US stocks

Gross margin
63.8%

Higher than 77% of US stocks

Operating margin
−6.4%

Higher than 27% of US stocks

Net margin
−6.7%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−40.8%

Higher than 24% of US stocks

Return on assets
−4.0%

Higher than 33% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Hims & Hers Health, Inc. (HIMS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Hims & Hers Health, Inc. has a market value of $4.1B and an enterprise value of $5.0B.

  • Revenue in the twelve months to 30 June 2026: $2.6B. The latest quarter grew 48.6% year on year.

  • Net income over the same four quarters: −$142.0M, a −5.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.63.

  • Free cash flow in the twelve months to 30 June 2026: $61.6M.

  • Shares outstanding: 233.3M.

  • Trailing P/E: 57.1×; forward P/E: 43.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Hims & Hers Health, Inc. employs 2,442 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

HIMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
HIMSHims & Hers Health, Inc.$4.1B12
AMLXAmylyx Pharmaceuticals, Inc.$3.5B60
LQDALiquidia Corp.$5.1B97
XERSXeris Biopharma Holdings, Inc.$3.1B100
SUPN.1Supernus, Inc.$6.0B89
LNTHLantheus Holdings, Inc.$6.6B98
SUPNSupernus Pharmaceuticals, Inc.$2.4B—

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Hims & Hers Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HIMS news & analysis

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC · 18 Nov 2026neutral

Hims & Hers said it is beginning the rollout of its Peptides+ platform with five U.S.-compounded offerings: sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine. The company said none of these formulations is FDA-approved.

Why it matters — The rollout adds peptide and longevity treatments to Hims & Hers’ offerings, while their lack of FDA approval is relevant context for investors following the company.

Hims & Hers Launches Peptides+, a New Clinically-Guided Specialty for Access to Personalized, Proactive Health

Business Wire · 18 Nov 2026positive

Hims & Hers announced Peptides+, a new specialty offering clinically guided protocols. After a clinical visit, eligible customers may receive a personalized plan that can include up to five treatments, depending on their provider’s assessment.

Why it matters — The launch adds a new specialty to Hims & Hers’ health offerings, which may be relevant to investors tracking its services and product expansion.

Hims & Hers: Further Expanding Internationally

Seeking Alpha · 16 Nov 2026neutral

The article highlights international expansion as a key growth driver for Hims & Hers, citing raised revenue guidance of at least $650 million in 2026 and expectations of $1 billion in 2027. It also notes near-term pressures, including a Q3 gross margin decline to 57% and a sequential subscriber decrease of 103,000.

Why it matters — HIMS watchers may weigh the company’s international growth prospects against the reported margin and subscriber headwinds.

Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy?

The Motley Fool · 16 Nov 2026negative

Hims & Hers Health reported 49% revenue growth last quarter but incurred a loss as gross margins deteriorated.

Why it matters — The combination of strong revenue growth and weaker gross margins is relevant to HIMS watchers assessing the company’s latest results.

Why Is Hims Stock Crashing, and is it a Buying Opportunity?

The Motley Fool · 14 Nov 2026negative

The Motley Fool’s headline asks why Hims stock is falling and whether it may present a buying opportunity. The excerpt says revenue is increasing, while operating expenses are also rising.

Why it matters — HIMS watchers may want to weigh the company’s revenue growth against higher operating expenses when assessing the report.

FAQ

Frequently asked questions about HIMS stock

What is the HIMS stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Hims & Hers Health, Inc. have a median 12-month price target of $26, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HIMS stock a buy right now?

Of the 15 analysts covering Hims & Hers Health, Inc., 3 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hims & Hers Health, Inc. 12 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HIMS?

As at 17 Nov 2026, Hims & Hers Health, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (58 of 100).

Will HIMS stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +52.5% from the last close, and Ticker Nerd's factor model ranks Hims & Hers Health, Inc. 12 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HIMS stock forecast for 2030?

No analyst covering Hims & Hers Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HIMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.

How has HIMS stock performed over the past year?

Hims & Hers Health, Inc. returned -53.0% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Hims & Hers Health, Inc. do?

Hims & Hers Health, Inc. Class A Common Stock is the equity of Hims & Hers Health, a consumer-focused digital health and telehealth platform.

What is the latest news on HIMS?

The most recent item we track (CNBC, 18 Nov 2026): "Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy". Hims & Hers said it is beginning the rollout of its Peptides+ platform with five U.S.-compounded offerings: sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine. The company said none of these formulations is FDA-approved.

Company

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. Class A Common Stock is the equity of Hims & Hers Health, a consumer-focused digital health and telehealth platform. Hims & Hers connects customers with licensed healthcare professionals through its websites and mobile app, offering online consultations, prescriptions, laboratory testing, and follow-up support. Its current product and service lineup spans sexual health, hair care, mental health, weight loss, dermatology, and general wellness, with a mix of prescription and over-the-counter offerings. The company also provides personalized health solutions and fulfillment services through its branded consumer platform. Based in San Francisco and founded in 2017, Hims & Hers operates in the healthcare market as a direct-to-consumer service provider that combines clinical access, digital technology, and pharmacy-enabled delivery.

CEO Mr. Andrew Dudum · 2,442 employees · United States · https://www.hims.com